Ładuje się......
Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma
Cetuximab, an EGFR-blocking antibody, is currently approved for treatment of metastatic head and neck squamous cell carcinoma (HNSCC), but its response rate is limited. In addition to blocking EGFR-stimulated cell signaling, cetuximab can induce endocytosis of ASCT2, a glutamine transporter associat...
Zapisane w:
| Wydane w: | JCI Insight |
|---|---|
| Główni autorzy: | , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Society for Clinical Investigation
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6795401/ https://ncbi.nlm.nih.gov/pubmed/31578313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131106 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|